A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations - Trial NCT06101134
Access comprehensive clinical trial information for NCT06101134 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on Melanoma. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Bristol-Myers Squibb
Timeline & Enrollment
Phase 2
Dec 29, 2023
Aug 31, 2027
Primary Outcome
Number of participants that prefer subcutaneous (SC) route of administration as assessed by Question 7 of the Patient Experience and Preference Questionnaire (PEPQ)
Summary
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous
 (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience
 data by route of administration. This study will also generate safety data which will further
 characterize the safety profile of patients switching the route of administration from
 intravenous (IV) to SC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06101134
Non-Device Trial